Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ARGUN AKCAKANAT and MING ZHAO.
ARGUN AKCAKANAT
Connection Strength
0.232
MING ZHAO
  1. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
    View in: PubMed
    Score: 0.051
  2. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res. 2021 11 01; 81(21):5572-5581.
    View in: PubMed
    Score: 0.050
  3. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 03 04; 23(1):29.
    View in: PubMed
    Score: 0.048
  4. Targeting PI3K? alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget. 2020 Mar 17; 11(11):969-981.
    View in: PubMed
    Score: 0.045
  5. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.